Entrar/Registro  
INICIO ENGLISH
 
Médica Sur
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Médica Sur >Año 2002, No. 4


Martínez SH, Herrera GA, Aguilar PJL, Garza SJG
Perfusión aislada de extremidad. Una alternativa a la amputación en tumores avanzados por melanoma, sarcomas y otros tumores irresecables de las extremidades
Med Sur 2002; 9 (4)

Idioma: Español
Referencias bibliográficas: 56
Paginas: 148-155
Archivo PDF: 149.66 Kb.


Texto completo




RESUMEN

La perfusión aislada de extremidad es una técnica utilizada desde 1959 en el tratamiento del melanoma maligno con resultados satisfactorios en las lesiones en tránsito. Con los diferentes esquemas de drogas para perfusión se han obtenido respuestas globales que oscilan del 80% al 100%, lo que ha permitido ampliar las indicaciones en melanoma a los pacientes con lesiones primarias irresecables o concomitantes a enfermedad metastásica a distancia. Con estos resultados y la aparición en el mercado del factor de necrosis tumoral se extendió su uso a otras neoplasias. En sarcomas de tejidos blandos de las extremidades se han obtenidos respuestas satisfactorias en el 95% de los casos, con la mejor respuesta patológica completa jamás obtenida por otro método neoadyuvante. Actualmente el uso de la perfusión aislada de extremidad permite el salvamento de una extremidad en 90% de los casos.


Palabras clave: Perfusión aislada de extremidad, melanoma, sarcoma, cáncer de piel.


REFERENCIAS

  1. Creech DG. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 4:616-32.

  2. Creech O, Ryan RF, Krementz ET. Treatment of malignant melanoma by isolation perfusion technique. JAMA 1959; 69: 339-43.

  3. Benckhuijsen C, Kroon BB, Van Geel AN et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evolution of drugs kinetics. Eur J Surg Oncol 1988, 14:157-63.

  4. Lebrun J, Smets W. Regional perfusion of chemotherapeutic agents by extracorporeal circulation in melphalangy. Evaluation of the results. Acta Chir Belg 1965; 64: 961-6.

  5. Cavaliere R, Ciocatto EC, Giovanella BC et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-81.

  6. Lejeune F. Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma. Pathol Biol 1990; 38:883-4.

  7. Lienard D, Ewalenko P, Delmotte JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.

  8. Lejeune FJ, Deloof T, Ewalenko P. Objective regression of unexcised melanoma in transit metastases after hyperthermic isolation perfusion of the limbs with Melphalan. Recent Results. Cancer Res 1983; 86: 268-76.

  9. Minor DR, Allen RE, Alberts D et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55: 2638-44.

  10. Skene AI, Bulman AS, Williams TR et al. Hyperthermic isolated perfusion in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77: 765-7.

  11. Kettelhack Ch, Kraus Th, Hupp Th. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990; 16: 370-5.

  12. Klasse JM, Kroon BBR, Van Geel AN et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993, 80:1124-6.

  13. Stheling JS, Giovanella BC, De Ipolyi PD et al. Results of hypertermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339-48.

  14. Liénard D, Eggermont AMM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated Limb Perfusion in primary and recurrent melanoma: Indications and results. Sem Surg Oncol 1998; 14: 202-9.

  15. Klasse JM, Kroon BB, Van Geel AN et al. A retrospective comparative study evaluating the results of a single perfusion versus double perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990-4.

  16. Rosin RD and Westbury G. Isolated limb perfusión for malignant melanoma. Practitioner 1980; 224: 1031-6.

  17. Liénard D, Eggermont AMM, Schaffrordt-Koops H et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan with or without interferon-gamma for the treatment of in transit melanoma metastases. A multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.

  18. Vaglini M, Andreola S, Attili A et al. Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities. Tumori 1985; 71: 355-9.

  19. Storm FK, Morton DL. Value of therapeutic hyperthermic lymb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150: 32-5.

  20. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995; 19: 363-8.

  21. Cavaliere R, Calabro A, Di Filippo F et al. Prognostic parameters in limb recurrent melanoma treated with hyperthermic antiblastic perfusión [abstract]. Proceedings of the International Conference on Regional Cancer Treatment. Ulm. 1987, G7:163.

  22. Di Filippo F, Calabro A, Giannarelli D et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-61.

  23. Kroon BBR, Klasse JM, van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusión for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-6

  24. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-12.

  25. Hill S, Fawcett WJ, Shledon J et al. Loe dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusión. Br J Surg 1993; 80: 995-7.

  26. Vaglini M, Belli F, Ammatuna M et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high dose TNF, gamma INF and melphalan. Cancer 1994; 73: 483-92.

  27. Eggermont AMM, Liénard D, Schraffordt Koops H et al. High dose tumor necrosis factor alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg cancer Treat 1995;7: 32-6.

  28. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor and interferon gamma: results of tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-89.

  29. Eggermont AMM, ten Hagen TLM. Isolated Limb Perfusion for extremity soft-tissue Sarcomas, in transit metastases, and other unresectable tumors: Credits, debits and future perspectives. Current Oncology Reports 2001; 3: 359-67.

  30. Di Filippo F, Anza M, Rossi CR et al. The application of hyperthermia in regional chemotherapy. Sem Surg Oncol 1998;14: 215-23.

  31. Kremetz ET, Carter RD, Sutherland CM et al. Regional chemotherapy for melanoma. A 35 year experience. Ann Surg 1994; 220: 520-35.

  32. Ghussen F, Nagel K, Groth W et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984; 200: 764-6.

  33. Eggermont AMM: in Strategies in Adjuvant Therapy. Kirkwood J. 1st Ed. 2000. Martin Dunitz Ltd. London. Pp 233-46.

  34. Gustafson M. Invar. M, Lev-Slush D et al. Is a local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991; 67: 2083-6.

  35. Stotter AT, A?Hern RP, Fisher C et al. The influence of local recurrence of extremity soft tissue sarcoma on metastases and survival. Cancer 1990; 65: 1119-29.

  36. Lewis JJ, Leung D, Heslin M, Wooddruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1997; 15: 646-52.

  37. Kehoan ML. Adult Sost Tissue Sarcomas. Educational Book. ASCO 2002. pp 599-602.

  38. McCarter MD, Jaques DP, Brennan MF. Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin N Am 2002: 11-22.

  39. Espat NJ, Lewis JJ. The biological significance of failure at the primary site on ultimate survival in soft tissue sarcoma. Sem Radiation Oncol 1999; 9: 369-77.

  40. Levine EA. Prognostic factors in soft tissue sarcoma. Sem Surg Oncol 1999;17: 23-32.

  41. Cany L, Bui NB, Stockle E et al. Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult. Bull Cancer 1992; 79: 1077-85.

  42. Rahoty P, Konya A. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol 1993;19: 641-5.

  43. Meric F, Milas M, Hunt K et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 2000; 18: 3378-3383.

  44. Shreyaskumar RP, Benjamin RS. New chemotherapeutic strategies for soft tissue sarcomas. Sem Surg Oncol 1999; 17: 47-51.

  45. Levine EA, Trippon EM, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcoma. Cancer 1993; 71: 3685-9.

  46. Wanebo HJ, Temple WJ, Popp MB et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995; 75: 2299-306.

  47. Temple WJ, Temple CL, Arthur K et al. Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Oncol 1997; 4: 586-90.

  48. Toma S, Palumbo R, Vincente M et al. Concomitant doxorrubicin by continuous infusion and radiotherapy at low doses in locally advanced and/or metastasic soft tissue sarcoma (STS): long term results of a phase II study [abstract]. Proc Am Soc Clin Oncol 1995; 14: 520.

  49. Eiber F, Giuliano A, Huth JH et al. Neoadjuvant chemotherapy, radiation, and limited surgery for high grade sarcoma of the extremity. In: Ryan JR, Baker LO (eds): “recents concepts in sarcoma treatment” Dordrecht. The Netherlands, Kluwer Academic Publishers; 1988: 115-22.

  50. Eiber F, Giuliano A, Huth JH et al. Intravenous (IV) vs intraarterial (IA) adriamycin, 2800 radiation and surgical excision for extremity soft tissue sarcoma: a randomized prospective [abstract]. Proc Am Soc Clin Oncol 1990; 9: 309.

  51. Goodnight JE, Bargar WL, Voegeli T, Blasidell FW et al. Limb sparing surgery for extremity sarcomas after preoperative intraarterial doxorrubicin and radiation therapy. Am J Surg 1985; 150: 109-13.

  52. Cormier J, Shrayaskumar RP, Herzog C, et al. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment related toxicity in 43 patients with sarcoma. Cancer 2001, 92: 1550-5.

  53. Eiber FC, Gerald R, Eckrardt J et al. Treatment induced pathologic necoris: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19: 3203-9.

  54. Edmonson JH, Petersen IA, Shives TC et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas. Initial treatment with ifosfamide, mitomycin, doxorrubicin and cisplatinum plus Granulocyte-Macrophage-Colony-Stimulating-factor. Cancer 2002; 94: 786-92.

  55. Di Filippo F, Giannarelli D, Botti C et al. Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. Ann Oncol 1992; 3(Suppl 2): S71-4.

  56. Rossi CR, Vecchiato A, Da Pian PP et al. Adriamycin in hyperthermic perfusion for advanced limb sarcomas. Ann Oncol 1992; 3(Suppl 2): S111-3.

  57. Lejeune FJ, Kroon BBR, Di Filippo et al. Isolated limb perfusion. The European experience. Surg Oncol Clin 2001; 10: 821-32.

  58. Eggermont AMM, Schrafordt Koops, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764.

  59. Eggermont AMM, Schrafordt Koops, Klausner JM et al. Isolated limb perfusion with high dose tumor necrosis factor-alpha in combination with interferon gamma and melphalan for nonresectable extremity soft tissue sarcomas. A multicenter trial. J Clin Oncol 1996; 14: 2653-65.

  60. Hill S, Thomas JM. Low dose tumor necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res 1994; 4(Suppl 1): 31-4.

  61. Santinami M, Deraco M, Azzarelli A et al. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor-alpha and melphalan. Tumori 1996; 82: 579-84.

  62. Olieman AF, Liénard D, Eggermont AM et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha, interferon gamma and melphalan for locally advanced nonmelanoma skin tumors of the extremities. A multicenter study. Arch Surg 1999; 134: 303-7.

  63. Bickels J, Manusama ER, Gutman M et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25: 509-14.

  64. Daryanani D, De Vries EG, Guchelar HJ et al. Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol 2000; 26: 792-7.

  65. Rossi RC, Foletto M, Pilati P, Mocellin S, Lise M. Isolated Limb Perfusion in advanced cutaneous Melanoma. Sem Oncol 2002, 29(4): 400-9.

  66. Eggermont AMM, Martin Gore. European approach to Adjuvant treatment to intermediate and high risk Malignant Melanoma. Sem Oncol 2002: 29(4): 382-8.



>Revistas >Médica Sur >Año2002, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019